Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
Tweet
Share
E-mail
Get Alerts AMLX Hot Sheet
Join SI Premium – FREE
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of ($0.92), $0.01 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $1.42 million.
For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Centuri Holdings, Inc. (CTRI) Misses Q3 EPS by 14c ; Offers Guidance
- Netscout Systems (NTCT) Tops Q2 EPS by 2c ; Offers Guidance
- Nova Measuring Instruments (NVMI) Tops Q3 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
